USP30 and idiopathic pulmonary fibrosis: In addition, Mission Therapeutics is exploring USP30 inhibitors in the pre-clinical stage for the treatment of IPF and other mitochondrial disorders, indicating a potential druggable role of USP30 in IPF therapy (Harrigan et al., 2018).